MAPK1 and breast carcinoma: H high Ras-ERK pathway activity and higher expression of several gene sets of the Ras/Raf/MEK/ERK pathway were more common in TNBCs than other molecular subtypes of breast cancer, which suggests that inhibition of MEK signaling should be effective in the treatment of TNBCs [100,136,137,138].